News

Johnson & Johnson loses stent patent battle

Johnson & Johnson (NYSE:JNJ) has lost a court battle over its drug-coated stent patents after a New Jersey federal judge ruled that stents marketed by Boston Scientific (NYSE:BSX) Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) had not infringed stent patents held by the New Brunswick, New Jersey company. Despite the ruling, a Johnson & Johnson spokeswoman […]

Johnson & Johnson (NYSE:JNJ) has lost a court battle over its drug-coated stent patents after a New Jersey federal judge ruled that stents marketed by Boston Scientific (NYSE:BSX) Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) had not infringed stent patents held by the New Brunswick, New Jersey company.

Despite the ruling, a Johnson & Johnson spokeswoman said in an email that the company would appeal the decision.

Johnson & Johnson ended its drug-coated stent business last year and exited a lucrative $4 billion market amidst setbacks in its business that included manufacturing problems, unfavorable patent decisions and greater competition.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

In 2010, Boston Scientific agreed to pay J&J $1.73 billion to end other patent lawsuits between the companies over stent technology.